The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
How often is the planned dose intensity of XELOX and FOLFOX administered to colon cancer patients older than age 65 in clinical practice?
G. Romano
No relevant relationships to disclose
M. Colonna
No relevant relationships to disclose
A. Gnoni
No relevant relationships to disclose
S. A. Leo
No relevant relationships to disclose
C. Nuzzo
No relevant relationships to disclose
R. Forcignano
No relevant relationships to disclose
E. Veltri
No relevant relationships to disclose
V. Lorusso
No relevant relationships to disclose